Single User License
INR 168550
Site License
INR 337100
Corporate User License
INR 505650

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016


  Request for Sample Report

Executive Summary

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016" provides an overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) clinical trials scenario. This report provides top line data relating to the clinical trials on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Central and South America 13

Clinical Trials by G7 Countries: Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials 14

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials 30

Prominent Drugs 32

Clinical Trial Profile Snapshots 33

Appendix 93

Abbreviations 93

Definitions 93

Research Methodology 94

Secondary Research 94

About GlobalData 95

Contact Us 95

Disclaimer 95

Source 96

List of Figures

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12

Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials, G7 Countries (%), 2016* 14

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials, E7 Countries (%), 2016* 18

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32

GlobalData Methodology 94

List of Tables

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Region, 2016* 6

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13

Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials, G7 Countries (%), 2016* 15

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17

Proportion of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) to Immunology Clinical Trials, E7 Countries (%), 2016* 19

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Phase, 2016* 22

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, ChemoCentryx, Inc., Zenyaku Kogyo Co Ltd, Tianjin CanSino Biotechnology Inc., Shenzhen Kangtai Biological Products Co., Ltd., Nippon Kayaku Co., Ltd., Bristol-Myers Squibb Company, AbbVie Inc, Abbott Laboratories

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com